ExodusPoint Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

ExodusPoint Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-86,720	Closed	-$668K	–	1643
2025 Q4	$668K	Buy	+86,720	New	+$684K	0.01%	1116
2025 Q2	–	Sell	-199,358	Closed	-$634K	–	1548
2025 Q1	$634K	Buy	199,358 +185,842	+1,375%	+$875K	0.01%	1054
2024 Q4	$72K	Buy	+13,516	New	+$101K	﹤0.01%	1416
2022 Q2	–	Sell	-25,563	Closed	-$42K	–	2015
2022 Q1	$42K	Buy	+25,563	New	+$46.8K	﹤0.01%	2074
2020 Q1	–	Sell	-22,861	Closed	-$124K	–	1160
2019 Q4	$124K	Buy	+22,861	New	+$80K	﹤0.01%	1407

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ExodusPoint Capital Management's CRVS Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 86,720 shares — an estimated $668K sold.

ExodusPoint Capital Management first reported a position in CRVS in Q4 2019 and held it in 5 quarters. The position peaked at $668K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

ExodusPoint Capital Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 86,720 Corvus Pharmaceuticals shares in Q1 2026, an estimated $668K.
ExodusPoint Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2019 and held it in 5 quarters.
ExodusPoint Capital Management's Corvus Pharmaceuticals position peaked at $668K in Q4 2025.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.